Nitinotes

About Nitinotes

Nitinotes is an Israeli-based, privately-held medical device company, founded in 2014 by Irit Yaniv and Tamir Wolf. It operates from Caesarea, Israel, within the surgical devices and health-tech sectors. The company is focused on addressing the global obesity epidemic by developing less invasive solutions for patients for whom traditional bariatric surgery is not an option.

The company's business revolves around the development and future commercialization of its flagship product, the EndoZip™ system. This system is designed for endoscopic sleeve gastroplasty (ESG), a procedure that reduces stomach volume without surgery. The business model targets hospitals and private clinics, with revenue expected from the sale of the single-use EndoZip™ devices. Nitinotes serves a market of over 700 million individuals with class I and II obesity who may not qualify for or desire more invasive surgical options. To date, the company has raised approximately $33.9 million through several funding rounds, with investors including MTIP, Elron Ventures, Techwald Holdings, Arkin Capital, and Peregrine Ventures.

The EndoZip™ is a fully automated, robotic suturing system for performing endoscopic gastroplasty. Inserted orally through an overtube, the device utilizes a standard pediatric scope for visualization. Its core function is to place durable, consistent sutures in the stomach wall to reduce its volume. An articulating head allows for precise positioning, and a suction mechanism draws the stomach walls into the device's chamber for full-thickness suturing. A key feature is its automation; the surgeon activates the motorized helical needle with a button press, which standardizes the procedure and is intended to reduce the learning curve for physicians. This minimally invasive procedure is designed to take about 30 minutes, potentially allowing patients to be released the same day. Clinical studies have shown promising results, and the company received FDA Investigational Device Exemption (IDE) approval in June 2025 to begin pivotal trials in the U.S.